Fig. 3: Validation of the predictive power of LCP1 and ADPGK in a patient cohort.
From: Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
a Representative images of patients with irAEs and without irAEs through immunohistochemical (IHC) staining with antibodies against ADPGK and LCP1. Image size: 379 × 379 μm2; scale bar: 100 μm. b Quantification of LCP1 and ADPGK IHC staining signals. Comparison between patients with irAE or without irAE is conducted by unpaired two-sided Student’s t test. c Geometric mean of LCP1 and ADPGK staining signals. A comparison between patients with irAE and without irAE is conducted by unpaired two-sided Student’s t test. d ROC curve of the LCP1, ADPGK, LCP1 + ADPGK in the validation cohort (n = 28). The boxes indicate the median ± 1 quartile, with whiskers extending from the hinge to the smallest or largest value within 1.5 interquartile range from the box boundaries. ROC receiver-operating characteristic, AUC area under the receiver-operating characteristic curve.
